Hypothyroidism is among the most prevalent endocrine disorders in clinical practice, affecting approximately 5% of the general population and rising to 10–15% in women over age 60. The pharmacological management appears deceptively straightforward, yet optimizing levothyroxine therapy demands precision: dosing varies substantially across body weight, age, residual thyroid function, and absorptive capacity; thyroid-stimulating hormone (TSH) targets differ by clinical context from standard replacement to pregnancy to post-thyroid cancer suppression; and a subset of patients remains persistently symptomatic despite biochemically normal TSH. This module covers the full clinical pharmacology of hypothyroidism management, from distinguishing primary from central hypothyroidism and establishing evidence-based dosing frameworks, through special population considerations, the contested role of combination T4/T3 therapy, the pharmacological emergency of myxedema coma, and the growing problem of drug-induced hypothyroidism.
Primary hypothyroidism arises from intrinsic thyroid gland failure, and thyroid-stimulating hormone (TSH) rises as the pituitary responds to inadequate thyroid hormone output. Hashimoto's thyroiditis (chronic autoimmune thyroiditis) is the dominant cause in iodine-sufficient populations, mediated by cluster of differentiation 4 (CD4+) T-cell-driven follicular destruction and TPO (thyroid peroxidase) and thyroglobulin (Tg) autoantibodies. Post-ablative hypothyroidism following radioactive iodine (RAI) or thyroidectomy is the second most common cause; levothyroxine requirements are predictable and often full replacement from initiation, since residual thyroid function is absent. Iatrogenic causes include thionamide overtreatment, lithium, amiodarone, and immune checkpoint inhibitors (ICIs), each covered in Section 6. In primary hypothyroidism, TSH is the primary diagnostic and monitoring endpoint: a TSH above the laboratory reference range with a low or low-normal free thyroxine (T4) confirms the diagnosis, and TSH normalizes reliably once adequate levothyroxine replacement is achieved.1,2
Central hypothyroidism, arising from pituitary or hypothalamic disease, presents with a distinctly different biochemical pattern that must be recognized to avoid misdiagnosis. TSH is low, inappropriately normal, or mildly elevated despite subnormal free T4, because the pituitary cannot mount a normal TSH response to thyroid hormone deficiency. Common causes include pituitary macroadenoma, pituitary surgery or radiation, traumatic brain injury, Sheehan's syndrome (postpartum pituitary infarction), and infiltrative diseases such as sarcoidosis and hemochromatosis. Dopamine, glucocorticoids, and somatostatin analogues transiently suppress TSH and can mimic central hypothyroidism biochemically; these pharmacological causes should be excluded before structural pituitary disease is diagnosed. In central hypothyroidism, free T4 (not TSH) is the primary monitoring endpoint, because TSH may remain low or normal even on adequate replacement. The target free T4 is typically in the upper half of the reference range, verified at a stable dose after at least 6 weeks.1,2
Subclinical hypothyroidism, defined as a TSH above the upper reference limit with a normal free T4, represents a biochemical state rather than a clinical diagnosis and requires individualized management decisions. The two-tier classification separates mild subclinical hypothyroidism (TSH 4.5–10 mIU/L) from severe subclinical hypothyroidism (TSH above 10 mIU/L). The American Thyroid Association (ATA) and the European Thyroid Association (ETA) recommend treatment when TSH exceeds 10 mIU/L regardless of symptoms, and in younger patients (under 65) with TSH 4.5–10 mIU/L who have symptoms, positive anti-TPO (anti-thyroid peroxidase) antibodies, dyslipidemia, or pregnancy risk. In elderly patients (over 70) with TSH 4.5–10 mIU/L and no symptoms, observational data suggest that mild TSH elevation may be a normal aging variant and that levothyroxine treatment does not improve outcomes, as demonstrated by the TRUST (Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism) randomized controlled trial.3,4
In primary hypothyroidism, TSH is the endpoint: normalize TSH and free T4 follows. In central hypothyroidism, TSH cannot be used as a monitoring endpoint because pituitary disease prevents the normal TSH response. Use free T4, targeting the upper half of the reference range, checked 6 weeks after any dose change. Failing to recognize central hypothyroidism and using TSH as the endpoint leads to systematic under-replacement, since TSH remains low or normal even at subtherapeutic levothyroxine doses.
Full levothyroxine replacement in adults with complete hypothyroidism (post-thyroidectomy or post-ablation) requires approximately 1.6 mcg/kg of actual body weight per day, typically yielding a starting dose of 88–125 mcg in most adults. In practice, dose rounding to the nearest available tablet strength (25, 50, 75, 88, 100, 112, 125, 137, 150 mcg) is routine. Lean body weight is more appropriate than total body weight in obese patients, since adipose tissue does not proportionally increase levothyroxine metabolism; using total weight in morbidly obese patients risks overtreatment. Patients with residual thyroid function, such as those with Hashimoto's thyroiditis who have not undergone ablation, typically require lower doses (1.0–1.3 mcg/kg/day) because endogenous secretion supplements exogenous replacement. After any dose initiation or change, thyroid-stimulating hormone (TSH) should be rechecked no sooner than 6 weeks, as the 6–7 day half-life of levothyroxine requires four to five half-lives to reach steady state. Rechecking earlier captures a non-equilibrium TSH and leads to inappropriate dose adjustments.1,5
TSH target ranges are not uniform and must be calibrated to the clinical context. For standard replacement in adults with primary hypothyroidism, a TSH of 0.5–2.5 mIU/L is widely used as a practical target in the lower half of the reference range, recognizing the intra-individual set point principle. In elderly patients (over 65), the American Thyroid Association (ATA) recommends a less aggressive target of 1.0–4.0 mIU/L, given that lower TSH in this population is associated with atrial fibrillation (AF) and bone mineral density loss, and that higher TSH may represent a normal aging variant. In pregnancy, TSH targets are trimester-specific: below 2.5 mIU/L in the first trimester (when maternal thyroid hormone is the sole source for fetal neurodevelopment) and below 3.0 mIU/L in the second and third trimesters, per 2017 ATA pregnancy guidelines. In differentiated thyroid cancer (DTC), TSH targets are risk-stratified: low-risk patients after successful ablation target TSH 0.5–2.0 mIU/L; high-risk patients with persistent disease target TSH below 0.1 mIU/L. The cardiovascular and skeletal costs of prolonged TSH suppression must be weighed against the oncological benefit at each risk tier.1,5,6
Levothyroxine formulation selection affects absorption reliability and should be tailored to patient circumstance. Standard sodium tablets require dissolution in gastric acid and are susceptible to pH-dependent absorption variability; patients with achlorhydria, proton pump inhibitor (PPI) use, gastric bypass, or celiac disease frequently require higher doses to compensate for impaired absorption. Liquid levothyroxine solution provides dose-independent bioavailability that is minimally affected by gastric pH, food, or co-administered medications, and is particularly valuable in patients with documented malabsorption, those requiring nasogastric (NG) tube administration, and those with persistently elevated TSH despite dose escalation on tablets. Soft gelatin capsules (Tirosint) occupy an intermediate position, outperforming tablets in malabsorptive states but requiring refrigeration. Switching between formulations, or between branded and generic levothyroxine, can alter bioavailability by up to 12.5% within the FDA-accepted bioequivalence window; any such switch warrants TSH recheck at 6 weeks.5,7
Standard adult replacement: 0.5–2.5 mIU/L. Elderly (>65 years): 1.0–4.0 mIU/L. Pregnancy first trimester: <2.5 mIU/L. Pregnancy second/third trimester: <3.0 mIU/L. DTC low risk: 0.5–2.0 mIU/L. DTC high risk: <0.1 mIU/L. Central hypothyroidism: use free T4 (upper half of reference range), not TSH. Never apply a single universal TSH target across all populations.
Elderly patients and those with ischemic heart disease or significant cardiac dysfunction require a cautious initiation strategy because levothyroxine increases cardiac oxygen demand and heart rate; abrupt full replacement can precipitate angina, myocardial infarction, or arrhythmia in patients with underlying coronary artery disease (CAD). The standard approach is to initiate at 12.5–25 mcg/day and uptitrate by 12.5–25 mcg every 4–6 weeks, aiming for the lower end of the age-appropriate thyroid-stimulating hormone (TSH) target range. In patients with severe CAD requiring urgent cardiac intervention, the procedure should not be delayed for thyroid optimization; correction of hypothyroidism should proceed postoperatively. There is no absolute contraindication to levothyroxine in cardiac disease, but the titration must be gradual and closely monitored. In frail elderly patients with TSH modestly elevated (4.5–10 mIU/L) and no symptoms, the evidence base for treatment is weak, and the TRUST (Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism) trial demonstrated no benefit of levothyroxine on quality of life, fatigue, or cognitive function at one year; a watchful waiting approach with repeat TSH in 3–6 months is appropriate.3,5
Pregnancy creates unique and clinically consequential challenges for thyroid management. Maternal thyroxine (T4) is the sole source of thyroid hormone for the fetus during the first trimester, before fetal thyroid gland development is complete at approximately 18–20 weeks. Adequate maternal T4 is essential for fetal cortical neuronal migration, cerebellar development, and myelination; even subclinical maternal hypothyroidism during the first trimester is associated with impaired neurodevelopmental outcomes in offspring. The demand for thyroid hormone increases by approximately 30–50% during pregnancy, driven by rising estrogen-induced thyroxine-binding globulin (TBG) production, placental type 3 deiodinase (D3) activity consuming maternal T4, and increased renal iodine clearance. Women with pre-existing hypothyroidism on stable levothyroxine doses almost universally require dose escalation in pregnancy, typically by 25–30% above pre-pregnancy dose, beginning as soon as pregnancy is confirmed. TSH should be monitored every 4 weeks during the first trimester and every 4–6 weeks thereafter. Women planning pregnancy should have pre-conception TSH normalized to below 2.5 mIU/L and should be counseled to contact their physician immediately on positive pregnancy test for dose assessment.6,8
Hypothyroidism in children and adolescents requires weight-based dosing that evolves rapidly with growth; pediatric doses are substantially higher on a per-kilogram basis than adult doses, particularly in neonates, reflecting the metabolically active period of brain development. Neonatal hypothyroidism (cretinism if untreated) detected by newborn screening requires immediate full replacement (10–15 mcg/kg/day in neonates) to prevent irreversible cognitive impairment; every week of delayed treatment in the neonatal period carries measurable developmental cost. Patients with malabsorptive conditions including celiac disease, short bowel syndrome, and inflammatory bowel disease (IBD) in a flare frequently require 20–30% higher levothyroxine doses and benefit from switching to liquid formulations. Bariatric surgery, particularly Roux-en-Y gastric bypass, impairs levothyroxine absorption by bypassing the proximal small intestine where most absorption occurs; post-surgical patients often require 30–50% dose increases and should have TSH monitored 6–8 weeks after surgery.5,7
Women with known hypothyroidism should increase their levothyroxine dose by approximately 25–30% (often achieved by taking two extra tablets per week) as soon as pregnancy is confirmed, without waiting for a physician visit. The first trimester window for fetal neurodevelopment is narrow and time-sensitive. TSH should be checked every 4 weeks in the first trimester and every 4–6 weeks thereafter. Pre-conception TSH below 2.5 mIU/L gives the widest margin of safety for the critical early weeks before the first prenatal visit.
A clinically important minority of patients treated with levothyroxine monotherapy report persistent symptoms including fatigue, cognitive slowing, depression, and weight difficulty despite thyroid-stimulating hormone (TSH) values within the reference range and normal free thyroxine (T4). The physiological hypothesis for this dissatisfaction invokes the DIO2 (deiodinase iodothyronine type 2) Thr92Ala polymorphism (rs225014): individuals homozygous for the Ala92 variant have reduced type 2 deiodinase (D2) catalytic efficiency in brain and pituitary, potentially impairing local T4-to-T3 (triiodothyronine) conversion in tissues that depend on D2 for intracellular T3 generation. In these patients, circulating T4 may be adequate by TSH metrics while brain T3 remains suboptimal. Observational data suggest that Ala92 homozygotes have worse psychological wellbeing on T4 monotherapy and a preference for combination therapy, but causality has not been established by definitive genetic trials.1,9
Randomized controlled trials of combination levothyroxine plus liothyronine (T3) therapy versus levothyroxine monotherapy have produced inconsistent results. The landmark Bunevicius 1999 trial reported superior mood and cognitive function with combination therapy, but subsequent larger randomized trials have not consistently replicated this finding. The Idrees 2020 and Saravanan trials demonstrated no significant benefit on quality of life, mood, or cognitive function in unselected hypothyroid patients. However, patient selection may have been insufficient in these trials: if the benefit is limited to DIO2 Ala92 homozygotes (approximately 16% of the population), an unselected cohort would be powered to detect only a small mean effect, diluted by the majority who derive no benefit. A predefined pharmacogenomic analysis within the Colorado trial (Nygaard 2017) did suggest that Ala92 homozygotes on combination therapy had superior wellbeing scores, but the sample was small.1,9
The 2014 American Thyroid Association (ATA) guidelines for hypothyroidism treatment state that there is insufficient evidence to recommend combination T4/T3 (levothyroxine plus liothyronine) therapy as first-line treatment, but acknowledge it may be considered as a trial in patients who remain symptomatic on adequate levothyroxine with TSH in the target range, after exclusion of other causes of persistent symptoms. If a trial is undertaken, liothyronine (T3) should be added at low dose (5–10 mcg once or twice daily), with a corresponding reduction in levothyroxine dose to avoid overtreatment; total thyroid hormone exposure should be monitored by free T4 and TSH. Extended-release T3 formulations under investigation aim to reduce the peak-to-trough fluctuation that limits conventional liothyronine use. The ATA advises reassessing after 3–6 months and discontinuing combination therapy if no symptomatic benefit is apparent. Combination therapy is contraindicated in cardiac disease, significant arrhythmia, advanced age with frailty, and osteoporosis without adequate bone protection.1
Persistent symptoms on adequate levothyroxine require systematic exclusion of other diagnoses before escalating to combination therapy. Check: iron deficiency anemia, celiac disease causing malabsorption, adrenal insufficiency (which can co-occur with autoimmune thyroid disease in polyglandular autoimmune syndrome), depression, sleep apnea, vitamin D deficiency, and perimenopause. Many patients incorrectly attribute non-specific symptoms to suboptimal thyroid replacement when an independent diagnosis is responsible.
Myxedema coma is a life-threatening decompensation of severe hypothyroidism characterized by depressed consciousness, hypothermia, hypoventilation, bradycardia, hyponatremia, and hypoglycemia. Despite its name, overt coma is not always present; altered mental status ranging from somnolence to stupor is more typical than complete unresponsiveness. The condition carries a mortality rate of 20–50% even with treatment, making early recognition and aggressive management essential. Precipitating factors include infection (most commonly pneumonia and urinary tract infection), cold exposure, medications (sedatives, opioids, anesthetics), trauma, stroke, and non-adherence to levothyroxine therapy. Myxedema coma most often occurs in elderly women with undiagnosed or inadequately treated hypothyroidism who are admitted for an unrelated acute illness and then decompensate because their hypothyroid reserve is exhausted by the physiological stress of acute illness.10,11
The pharmacological management of myxedema coma requires intravenous (IV) thyroid hormone because gastrointestinal (GI) absorption is unreliable in a comatose or hemodynamically unstable patient with reduced GI motility. The standard protocol begins with IV levothyroxine at a loading dose of 300–500 mcg (based on body weight and cardiac risk), followed by 50–100 mcg IV daily. The large initial dose is designed to rapidly saturate the expanded volume of distribution of thyroxine (T4) and restore circulating hormone levels; the dose is reduced in elderly patients or those with ischemic heart disease, where cardiovascular consequences of acute thyroid hormone loading must be weighed against the risk of undertreating the coma. The role of adjunctive IV liothyronine (T3) remains debated: proponents argue that impaired peripheral T4-to-T3 (triiodothyronine) conversion in severe illness makes T3 essential for prompt receptor-level effect; opponents note the risk of cardiac arrhythmia with exogenous T3 and the absence of randomized trial data demonstrating mortality benefit. Current practice at many centers uses a combination approach: low-dose IV T3 (5–20 mcg bolus, then 2.5–10 mcg every 8 hours) for the first 24–48 hours while IV T4 reaches steady state, discontinued once clinical condition stabilizes.10,11
Glucocorticoid co-administration is mandatory in the treatment of myxedema coma until adrenal insufficiency has been excluded. In severe hypothyroidism, the hypothalamic-pituitary-adrenal (HPA) axis may be simultaneously suppressed, either from panhypopituitarism in central hypothyroidism or from the blunted cortisol stress response seen in primary hypothyroidism itself. Administering thyroid hormone without glucocorticoid cover in a patient with undiagnosed adrenal insufficiency can precipitate an adrenal crisis by accelerating cortisol metabolism without a corresponding increase in cortisol production. Hydrocortisone 50–100 mg IV every 8 hours is the standard adjunctive protocol until adrenal function is confirmed by cosyntropin (synthetic adrenocorticotropic hormone, ACTH) stimulation testing. Supportive measures include passive rewarming, mechanical ventilation for hypoventilation, correction of hyponatremia with fluid restriction and hypertonic saline in severe cases, and glucose replacement for hypoglycemia. Precipitating infections must be identified and treated, since uncontrolled sepsis is among the highest-mortality drivers in myxedema coma.10,11
Never initiate thyroid hormone replacement in suspected myxedema coma without concurrent glucocorticoid cover. The combination of severe hypothyroidism and adrenal insufficiency (Schmidt's syndrome or panhypopituitarism) is not rare, and IV thyroid hormone accelerates cortisol catabolism while the adrenal gland cannot increase output. Give hydrocortisone 50–100 mg IV q8h empirically until adrenal function is confirmed. The cosyntropin stimulation test can be performed immediately before starting steroid cover without compromising the result.
Amiodarone-induced hypothyroidism (AIH) occurs in approximately 5–10% of amiodarone-treated patients and is far more common in iodine-sufficient geographic regions, where excess iodide load from amiodarone (which contains 37% iodine by weight and releases approximately 6 mg of free iodine daily, far exceeding the recommended daily allowance of 150 mcg) cannot be adequately cleared by the autoregulatory Wolff-Chaikoff mechanism. The resulting iodine excess chronically inhibits thyroid hormone synthesis. Thyroid-stimulating hormone (TSH) rises persistently (beyond the expected transient elevation in the first 3 months) and free thyroxine (T4) falls below the reference range. Treatment is straightforward: levothyroxine replacement is initiated and titrated to TSH within the standard target range. Amiodarone does not need to be discontinued for hypothyroidism management; the drug's 40–55 day elimination half-life means that even after discontinuation, iodine effects persist for months, so continuing amiodarone while treating the hypothyroidism is often the clinically appropriate course when the arrhythmia indication remains valid.12,13
Lithium-induced hypothyroidism affects 20–42% of long-term lithium users and occurs through two mechanisms: inhibition of thyroglobulin (Tg) proteolysis (reducing T4 and T3 secretion), and inhibition of thyroid hormone synthesis at the organification step. Lithium also promotes goiter through TSH-driven follicular hyperplasia secondary to the reduced hormone output. Thyroid function testing should be performed at baseline and every 6 months in lithium-treated patients; annual testing is adequate in stable patients without thyroid antibodies. Levothyroxine replacement is initiated for clinical hypothyroidism; lithium does not typically need to be discontinued, but psychiatric and endocrine management should be coordinated. Patients with pre-existing Hashimoto's thyroiditis who start lithium have substantially higher risk of accelerated progression to overt hypothyroidism and require more frequent monitoring.12,13
Immune checkpoint inhibitor (ICI)-related thyroid dysfunction follows a characteristic biphasic pattern that must be distinguished from Graves' disease and other thyroid disorders. The hyperthyroid phase, occurring in 5–10% of patients on anti-PD-1 (programmed death 1) or anti-PD-L1 (programmed death-ligand 1) monotherapy and 15–20% on combination anti-PD-1 plus anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) therapy, represents immune-mediated destructive thyroiditis releasing preformed hormone. It is typically painless, self-limited over 2–6 weeks, and does not require antithyroid drug treatment; beta-blockers may be used for symptomatic palpitations. The subsequent hypothyroid phase is often permanent and requires levothyroxine replacement. Thyroid-stimulating hormone (TSH) should be monitored every 4–6 weeks during ICI therapy, and each TSH elevation should prompt free T4 measurement to confirm the diagnosis before initiating replacement. ICI-related hypothyroidism is not an indication to interrupt cancer immunotherapy unless the patient is severely symptomatic.12,14
Tyrosine kinase inhibitors (TKIs), particularly sunitinib, sorafenib, and lenvatinib, cause hypothyroidism through several mechanisms including upregulation of type 3 deiodinase (D3) in tumor and normal tissues (increasing T4 inactivation), reduced sodium-iodide symporter (NIS) expression in thyroid follicular cells (reducing iodide uptake capacity), and direct thyroid vasculature damage producing ischemic thyroid injury. Sunitinib is associated with the highest incidence of hypothyroidism among TKIs, with TSH elevation in 36–85% of treated patients in some series, and many patients on prior thyroid cancer treatment already requiring levothyroxine suppression may find their dose requirements escalating substantially during tyrosine kinase inhibitor therapy. TSH should be monitored every 2–3 months in patients receiving these agents. A separate and under-recognized mechanism applies to thyroid cancer patients on levothyroxine suppression: inflammatory thyroiditis induced by these agents can accelerate remnant thyroid destruction, causing transient thyrotoxicosis before permanent hypothyroidism supervenes, an important distinction from de novo drug-induced hypothyroidism.12,14
Hyperthyroid phase (TSH suppressed, elevated free T4): this is destructive thyroiditis, not Graves' disease. No antithyroid drugs. Symptom management with propranolol if needed. Watch for transition to hypothyroid phase over 4–8 weeks. Hypothyroid phase (TSH elevated, low free T4): start levothyroxine. Do not interrupt immunotherapy for thyroid dysfunction alone unless the patient is severely symptomatic. Hypothyroidism from ICIs is usually permanent; plan for long-term replacement.
Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670–1751.
doi:10.1089/thy.2014.0028Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012;22(12):1200–1235.
doi:10.1089/thy.2012.0205Stott DJ, Rodondi N, Kearney PM, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med. 2017;376(26):2534–2544.
doi:10.1056/NEJMoa1603825Biondi B, Cappola AR, Cooper DS. Subclinical hypothyroidism: a review. JAMA. 2019;322(2):153–160.
doi:10.1001/jama.2019.9052Hennessey JV, Espaillat R. Diagnosis and management of subclinical hypothyroidism in elderly adults: a review of the literature. J Am Geriatr Soc. 2015;63(8):1663–1673.
doi:10.1111/jgs.13532Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017;27(3):315–389.
doi:10.1089/thy.2016.0457Ylli D, Klubo-Gwiezdzinska J, Wartofsky L. Thyroid emergencies. Pol Arch Intern Med. 2019;129(7–8):526–534.
doi:10.20452/pamw.14876Lazarus JH. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid. 1998;8(10):909–913.
doi:10.1089/thy.1998.8.909Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;116(10):2571–2579.
doi:10.1172/JCI29812Pimentel L, Hansen KN. Thyroid disease in the emergency department: a clinical and laboratory review. J Emerg Med. 2005;28(2):201–209.
doi:10.1016/j.jemermed.2004.08.020Kwaku MP, Burman KD. Myxedema coma. J Intensive Care Med. 2007;22(4):224–231.
doi:10.1177/0885066607301361Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–1421.
doi:10.1089/thy.2016.0229Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
doi:10.1089/thy.2015.0020Delivanis DA, Gustafson MP, Bornschlegl S, et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab. 2017;102(8):2770–2780.
doi:10.1210/jc.2017-00448